Royalty Pharma Future Growth
Future criteria checks 2/6
Royalty Pharma is forecast to grow earnings and revenue by 6.3% and 7.2% per annum respectively. EPS is expected to grow by 5.4% per annum. Return on equity is forecast to be 22.8% in 3 years.
Key information
6.3%
Earnings growth rate
5.4%
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | 7.2% |
| Future return on equity | 22.8% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13
Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,093 | 1,285 | 3,019 | 3,599 | 7 |
| 12/31/2025 | 2,872 | 1,110 | 2,721 | 3,303 | 7 |
| 12/31/2024 | 2,650 | 634 | 2,620 | 3,173 | 7 |
| 9/30/2024 | 2,266 | 1,145 | -212 | 2,799 | N/A |
| 6/30/2024 | 2,238 | 673 | 401 | 2,669 | N/A |
| 3/31/2024 | 2,239 | 799 | 1,019 | 2,619 | N/A |
| 12/31/2023 | 2,355 | 1,135 | 872 | 2,988 | N/A |
| 9/30/2023 | 2,324 | 184 | 1,422 | 2,785 | N/A |
| 6/30/2023 | 2,361 | 255 | 522 | 2,750 | N/A |
| 3/31/2023 | 2,359 | 332 | 374 | 2,718 | N/A |
| 12/31/2022 | 2,237 | 43 | 402 | 2,144 | N/A |
| 9/30/2022 | 2,247 | 507 | 401 | 2,064 | N/A |
| 6/30/2022 | 2,259 | 466 | 312 | 1,995 | N/A |
| 3/31/2022 | 2,278 | 602 | 263 | 1,952 | N/A |
| 12/31/2021 | 2,289 | 620 | -174 | 2,018 | N/A |
| 9/30/2021 | 2,286 | 783 | -732 | 2,093 | N/A |
| 6/30/2021 | 2,239 | 972 | -159 | 2,132 | N/A |
| 3/31/2021 | 2,195 | 493 | -496 | 2,090 | N/A |
| 12/31/2020 | 2,122 | 495 | -148 | 2,035 | N/A |
| 9/30/2020 | 2,008 | 1,745 | 104 | 1,947 | N/A |
| 6/30/2020 | 1,934 | 1,863 | 793 | 1,858 | N/A |
| 3/31/2020 | 1,880 | 2,052 | 1,093 | 1,705 | N/A |
| 12/31/2019 | 1,814 | 2,349 | -54 | 1,667 | N/A |
| 12/31/2018 | 1,795 | 1,378 | 1,349 | 1,618 | N/A |
| 12/31/2017 | 1,598 | 1,210 | N/A | 1,418 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPRX's forecast earnings growth (6.3% per year) is above the savings rate (2.6%).
Earnings vs Market: RPRX's earnings (6.3% per year) are forecast to grow slower than the US market (15.3% per year).
High Growth Earnings: RPRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: RPRX's revenue (7.2% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: RPRX's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (22.8%)